Analysis of the Medicinal Products for Human Use Authorised in the Russian Federation
https://doi.org/10.30895/1991-2919-2022-12-1-79-89
Abstract
The available range of medicinal products is growing every year.
The aim of the study was to analyse the range of medicines authorised in the Russian Federation.
Materials and methods: the analysis covered the data presented in the State Register of Medicines (as of June 2021) and the current regulations specifying the range of medicines.
Results: this article presents the results of analysis of medicines authorised in the Russian Federation, in terms of the following parameters: international non-proprietary names, trade names, groups according to the Anatomical Therapeutic Chemical Classification System, dosage forms, routes of administration, primary and secondary packaging, storage conditions, and shelf life. The analysis demonstrated that there are over 19 thousand medicines authorised in the Russian Federation, most of which are produced in Russia. The largest groups of medicines are antimicrobial products for systemic use, medicines for the treatment of nervous system and cardiovascular system disorders. The most common dosage form is tablets, and the most common primary packaging is vials. The most frequent storage temperature requirements are 15–25 and 2–8 °C. About half of all medicines have the shelf life of 3 years.
Conclusions: the data presented in this article can be used for unification of approaches to maintaining the State Register of Medicines, elaboration of reference books, and will be useful for medicine developers and manufacturers when planning and preparing regulatory submissions.
About the Authors
V. V. KosenkoRussian Federation
Valentina V. Kosenko, Cand. Sci. (Pharm.)
8/2 Petrovsky Blvd, Moscow 127051
R. I. Yagudina
Russian Federation
Roza I. Yagudina, Dr. Sci. (Pharm.), Professor
8/2 Petrovsky Blvd, Moscow 127051
O. A. Lednev
Russian Federation
Oleg A. Lednev
8/2 Petrovsky Blvd, Moscow 127051
SPIN-код РИНЦ: 9918-4729
V. G. Serpik
Russian Federation
Vyacheslav G. Serpik, Cand. Sci. (Pharm.), Associate Professor
8/2 Petrovsky Blvd, Moscow 127051
References
1. Petukhova EP, Belousov EA, Kiseleva VA, Karasev MM, Belousova OV. Study of the range of drugs by pharmacological groups. Izvestiya GGTU. Meditsina, farmatsiya = Izvestiya GSTU. Medicine, pharmacy. 2020;4:241–2 (In Russ.)
2. Dremova NB, Afanasyeva TG. The major trends of development of medical herbal medicines assortment. In: Actual problems of pharmaceutical science and practice. Vladikavkaz; 2014. P. 154–7 (In Russ.)
3. Khadzhieva ZD, Aleynikova NS. Analysis of nomenclature of ready medicines for external application. Uspekhi sovremennoy nauki i obrazovaniya = Success of Modern Science and Education. 2017;9(4):156–60 (In Russ.)
4. Saenko AYu, Popova EA, Kul IYa, Petrov AYu. Marketing study of suppositories included in the State Register of medicinal products of the Russian Federation. Remedium = Remedium. 2018;(3):29–32 (In Russ.)
5. Krychkovska AM, Puzanova IP, Gromovyk BP, Stasevych MV, Zhurakhivska LR, Khomenko IM, Novikov VP. Retrospective monitoring of changes of expiration dates of basic drugs. Ukrains’kiy biofarmatsevtichny zhurnal = Ukrainian Biopharmaceutical Journal. 2012;1–2:18–21 (In Ukrainian)
Supplementary files
Review
For citations:
Kosenko V.V., Yagudina R.I., Lednev O.A., Serpik V.G. Analysis of the Medicinal Products for Human Use Authorised in the Russian Federation. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2022;12(1):79-89. (In Russ.) https://doi.org/10.30895/1991-2919-2022-12-1-79-89